Substack · The Global Gambit's Substack · The Global Gambit
Boston Scientific Corp (NYSE: BSX) Q3 Outlook Dims Amid Growth Deceleration and Lowered Guidance
Reduced earnings targets, competitive pressures, and summer seasonality signal a cooling trajectory for the medical device maker following a record Q2.
Desde publicación +7,5 % α +8,8 p. p. vs S&P 500 · USD